Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar

Lara Marquez*, Antoine Chaillon, Kyi Par Soe, Derek Johnson, Jean-Marc Zosso, Andrea Incerti, Anne Loarec, Aude Nguyen, Josephine G Walker, Nyashadzaishe Mafirakureva, Vincent Lo Re III, Adriane Wynn, Craig McIntosh, Susan Kiene, Stephanie Brodine, Richard Garfein, Peter T Vickerman, Natasha Martin

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

5 Citations (Scopus)
67 Downloads (Pure)


Introduction Over half of those hepatitis C virus (HCV)/HIV coinfected live in low-income and middle-income countries, and many remain undiagnosed or untreated. In 2016, Médecins Sans Frontières (MSF) established a direct-acting antiviral (DAA) treatment programme for people HCV/HIV coinfected in Myanmar. The purpose of our study was to evaluate the real-world cost and cost-effectiveness of this programme, and potential cost-effectiveness if implemented by the Ministry of Health (MoH).

Methods Costs (patient-level microcosting) and treatment outcomes were collected from the MSF prospective cohort study in Dawei, Myanmar. A Markov model was used to assess cost-effectiveness of the programme compared with no HCV treatment from a health provider perspective. Estimated lifetime and healthcare costs (in 2017 US$) and health outcomes (in disability-adjusted life-years (DALYs)) were simulated to calculate the incremental cost-effectiveness ratio (ICER), compared with a willingness-to-pay threshold of per capita Gross Domestic Product in Myanmar ($1250). We evaluated cost-effectiveness with updated quality-assured generic DAA prices and potential cost-effectiveness of a proposed simplified treatment protocol with updated DAA prices if implemented by the MoH.

Results From November 2016 to October 2017, 122 with HIV/HCV-coinfected patients were treated with DAAs (46% with cirrhosis), 96% (n=117) achieved sustained virological response. Mean treatment costs were $1229 (without cirrhosis) and $1971 (with cirrhosis), with DAA drugs being the largest contributor to cost. Compared with no treatment, the program was cost-effective (ICER $634/DALY averted); more so with updated prices for quality-assured generic DAAs (ICER $488/DALY averted). A simplified treatment protocol delivered by the MoH could be cost-effective if associated with similar outcomes (ICER $316/DALY averted).

Conclusions Using MSF programme data, the DAA treatment programme for HCV among HIV-coinfected individuals is cost-effective in Myanmar, and even more so with updated DAA prices. A simplified treatment protocol could enhance cost-effectiveness if further rollout demonstrates it is not associated with worse treatment outcomes.
Original languageEnglish
Article numbere004181
Number of pages10
JournalBMJ Global Health
Issue number2
Publication statusPublished - 24 Feb 2021

Bibliographical note

Publisher Copyright:
© 2021 BMJ Publishing Group. All rights reserved.

Structured keywords

  • HEHP@Bristol


Dive into the research topics of 'Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar'. Together they form a unique fingerprint.

Cite this